

FLIESLER
DUBB
MEYER &
LOVEJOY LLP

FOUR EMBARCADERO CENTER, FOURTH FLOOR
SAN FRANCISCO, CALIFORNIA 94111-4156
TELEPHONE 415.362.3800
FACSIMILE 415.362.2928

C O N F I D E N T I A L

OFFICIAL

TO: USPTO-ART UNIT 1647
Examiner: J. Seharaseyon

FAX NO.: 703.872-9306

FAX RECEIVED

FROM: D. Benjamin Borson, Reg. No. 42,349

JUN 16 2003

RE: Application No. 09/856,704 - Filed 7/18/2001

GROUP 1600

DATE: June 13, 2003

Total Pages : 16

Original will follow by mail: No.

If you do not receive all of the pages, please call Bruce Ponte at 415.362.3800.

Attached hereto for filing:

1. RESPONSE B is in reply to the Office Action mailed April 22, 2003.
2. RESPONSE Transmittal Letter with Certificate of Transmittal and Fee Authorization.

NOTICE: This facsimile is confidential and may be attorney-client privileged, work product, and/or otherwise exempt from disclosure under applicable law.


This facsimile is intended only for the addressee and those authorized by the addressee to receive it. Any use, dissemination, distribution or copying of this facsimile by any others is prohibited. Any others receiving this facsimile are requested to notify FLIESLER DUBB MEYER & LOVEJOY LLP immediately by telephone or fax and to return the original facsimile to FLIESLER DUBB MEYER & LOVEJOY LLP.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>
Inventor(s): Vickers et al.)	
SC/Serial No.: 09/856,704)	Art Unit: 1647
Filed: July 18, 2001)	Examiner: J. Seharaseyon
Title: TREATMENT OF HYPERTENSION)	
)	

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner for Patents, the United States Patent and Trademark Office, Examining Group 1647 Facsimile No. (703) 872-9306 on June 13, 2003.

 (Attorney Signature)
D. Benjamin Borson, Reg. No. 42,349
Signature Date: June 13, 2003

RESPONSE TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted with this communication in connection with the above-identified application are the following:

 X A Response under 37 C.F.R. §1.111 to the Office Action dated April 22, 2003.

 X Applicant(s) qualify for small entity status under 37 C.F.R. §1.27.

The fee associated with this communication has been calculated as shown below:

 X Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established.

 X A fee for addition of claims under 37 C.F.R. §1.16 is due as follows:

FEES	Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	Rate Small Entity/Other Than Small Entity	Total
TOTAL CLAIMS (37 CFR 1.16(c))	21 -	12	1	X \$ 9.00	\$9.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	— *	— ***	—	X \$ 42.00	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(d))				+ \$140.00	\$
				TOTAL	\$9.00

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number of Previously Paid For" in this space is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" in this space is less than 3, enter "3".

The total fee required with this communication is \$9.00 and is to be paid as follows:

☒

Please charge Deposit Account No. 06-1325 in the amount of \$9.00.

☒

The Commissioner is hereby authorized to charge any deficiencies or credit overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

Date: June 13, 2003

By: D. Benjamin Borson
D. Benjamin Borson, Ph.D.
Reg. No. 42,349

FLIESLER DUBB MEYER & LOVEJOY LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
Telephone: (415) 362-3800

In the Title:

Please amend the title as follows:

TREATMENT OF HYPERTENSION USING GROWTH HORMONE IN
MAMMALS SUBJECTED TO FETAL PROGRAMMING